Gsk (GLAXF) Other financing activities (2009 - 2026)

Gsk's Other financing activities history runs 18 years deep, the most recent figure standing at $157.7 million for Q1 2026.

• In Q1 2026, Other financing activities rose 531.85% year-over-year to $157.7 million; the TTM figure through Mar 2026 stood at $99.5 million (up 847.21% YoY), while the FY2025 annual figure was $60.7 million, down 63.22% from the prior year.
• Other financing activities was $157.7 million for Q1 2026 at Gsk, up from -$33.3 million in the prior quarter.
• In the past five years, Other financing activities ranged from a high of $157.7 million in Q1 2026 to a low of -$36.5 million in Q1 2025.
• Historically, Other financing activities has averaged $40.8 million across 5 years, with a median of $10.4 million in 2024.
• The sharpest annual moves came in 2025 and 2026: Other financing activities plunged 387.88% in 2025, then surged 531.85% in 2026.
• A 5-year view of Other financing activities shows it stood at $9.4 million in 2022, then dropped by 7.41% to $8.7 million in 2023, then soared by 32.96% to $11.6 million in 2024, then slumped by 387.88% to -$33.3 million in 2025, then jumped by 574.34% to $157.7 million in 2026.
• The last three Other financing activities figures came in at $157.7 million (Q1 2026), -$33.3 million (Q4 2025), and -$36.5 million (Q1 2025), per Business Quant data.